Receive our newsletter – data, insights and analysis delivered to you
  1. Analysis
August 7, 2012

The patent cliff: plummeting blockbuster drug sales 2011-2012

After losing exclusivity on a number of blockbuster drugs, this year's Q2 financial reports revealed sales slumps for some of the industry's big sellers. Pharmaceutical Technology's infographic shows the impact patent expiration has had on sales of four major treatments.

By Nicholas Clapp

An unprecedented cycle of drug patent expiries is putting financial pressure on big pharma as previously rock-solid revenue streams begin to rapidly shrink.

Lipitor, Zyprexa, Plavix and Seroquel are just four of the biggest-selling drugs to have recently gone off-patent

Lipitor, Zyprexa, Plavix and Seroquel are just four of the biggest-selling drugs to have recently gone off-patent, with other major treatments set to follow in the months to come.

Companies are trying to offset plummeting sales by cutting back on R&D, as well as focusing on other drugs and emerging markets.

So it’s good news for patients waiting for affordable medicines, but tough times for pharma companies looking to protect the bottom line. Pharmaceutical Technology’s infographic illustrates some of the most pronounced sales drops experienced by companies facing the patent cliff.

For a more detailed breakdown of these effects, check out Drug Development Technology’s expired drugs round-up.

 

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU